Yarrow Bioscience, Inc. (YARW): Revenue
$570.0K
Year ended 2025-12-31
$482.0K
Trailing 12 months to 2026-06-30
+6.1%
3-year compound annual growth
-51.4%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $570.0K | +13.8% | 2026-02-27, From 2025-01-01 |
| 2024-12-31 | $501.0K | +18.2% | 2026-02-27, From 2024-01-01 |
| 2023-12-31 | $424.0K | -11.1% | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | $477.0K | -48.8% | 2024-03-01, From 2022-01-01 |
| 2021-12-31 | $931.0K | -95.6% | 2023-03-14, From 2021-01-01 |
| 2020-12-31 | $20.99M | n/m | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | $443.0K | -87.7% | 2021-03-04, From 2019-01-01 |
| 2018-12-31 | $3.60M | n/a | 2021-03-04, From 2018-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $570.0K | +13.8% |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $559.0K | -98.7% |
| PMGC Holdings Inc. (ELAB) | 2025-12-31 | $590.1K | n/a |
| Vaccinex, Inc. (VCNX) | 2024-12-31 | $601.0K | +5.4% |
| Quantum Cyber N.V. (QUCY) | 2025-12-31 | $537.1K | -39.9% |
| Lipella Pharmaceuticals Inc. (LIPO) | 2024-12-31 | $536.4K | +19.3% |
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | $642.0K | -71.7% |
| Polomar Health Services, Inc. (PMHS) | 2025-12-31 | $648.2K | n/m |
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | $500.0K | n/a |
Compare YARW, SLN, ELAB, VCNX side by side · Screen every company in Pharmaceutical Preparations ↗